• Share:

Monoclonal Antibodies: Melanoma

Melanoma
MAb MAA

I. Disialogangliosides
1. a) 136-2-E3-C11-3 (ME 36.1), IgG3, GD2 plus GD3
b) 136-2-E3-C11 (ME 36.2a), IgG2a, GD2 plus GD3 (switch variant), 30ug/ml
c) 136-2-E3-C11 (ME 36), IgG1 (switch variant)
2. a) 420-1-50-8-5 (ME 50.8), IgM (rat), GD3
b) 439-3-35-6-1-10 (ME 35.6), IgM, GD3
3. a) 131-1A7-2-2 (ME 311), IgG3, 9-0-acetyl GD3, 16ug/ml
b) 439-5-3-6 (ME 3.3), IgG3, 9-0-acetyl GD3
c) 440-3-73 (ME 7.3), IgG3, 9-0-acetyl GD3
d) 439-4-43-3 (43.3), IgG3, 9-0-acetyl GD3
4. 439-5-2-4-6 (ME 24), IgM, GD3 plus GD2
5. A2B5, IgM, GT3 (ATCC)

II. Cell-Cell and Cell-Substrate Receptors

1. a) 131-2H6-1-8 (ME 31.3), IgG1, chondroitin sulfate proteoglycan, >260 Kd, 10ug/ml
b) 0195-45 (ME 9545), IgG1, chondroitin sulfate proteoglycan, >260 Kd
2. a) 691-I-5-Nu4B (ME Nu4B), IgG2a, p130 Kd, 105 Kd, Vitronectin receptor, 34ug/ml
b) 403-77-4-2 (77), IgG1, p120/94 Kd, Vitronectin receptor (v3, epitope B) c) SAP-52-8, IgG1, 97 Kd, Vitronectin receptor (3), 32ug/ml
3. a) A32, IgG1, Mel-CAM/MUC18, p113 Kd, 13ug/ml, domain 2
b) MN-4, IgG1 k, (PVA-I-2C7-C), recMel-CAM, extracellular domain, domain 4 14ug/ml
c) MN-10, IgG1 k, (PVA-II-1H6-F10), recMel-CAM, extracellular domain, domains also not known for MN-17, MN-14, MN-17, MN-2
d) MN-3, IgG1 k, (PVA-2C5-A), recMel-CAM, extracellular domain, domain 1
e) MN-7, IgG1 k, (PVA-II-1 H3-D11 ), recMel-CAM, extracellular domain, domain 1
f) MN-9, IgG1 k, ( PVA-II-1B6-E11), recMel-CAM, extracellular domain, domain2
g) MN-5, IgG1 k, (PVA-I-4F5-A), recMel-CAM, extracellular domain, domain 5
h) MN-11, IgG1 k(PVA II-1F7-C8), recMel-CAM, extracellular domain, domain 2
i) MN-8, IgG1 k(PVA II-1H4-F10), recMel-CAM, extracellular domain, domain 2
4. a) PS/2, IgG2b, alpha 4 of VLA-4 (rat/mouse), (ATCC 1911-CRL)
b) TS2/16.2.1, IgG1, ß1 of VLA1ß (ATCC 243-HB), 90ug/ml
c) TS2/7.1.1, IgG1, alpha 1 of VLA-1 (ATCC 245-HB), 122ug/ml
5. P8B1, IgG2b, VCAM-1 (Hybridoma Bank, Iowa), blocking

III. Growth Factor Receptors
1. a) 200-3-G6-4-6 (ME 20.4), IgG1, NGF-receptor, 56ug/ml b) I182-11 (ME 82-11), IgG1, NGF-receptor, 40ug/ml
2. a) 425-3-75-5-4 (425), IgG2a, EGF-receptor b) 403-75-7 (75), IgG1, EGF-receptor
3. IR1, IgG1, Insulin receptor (ATCC)

II. Cell-Cell and Cell-Substrate Receptors

1. a) 131-2H6-1-8 (ME 31.3), IgG1, chondroitin sulfate proteoglycan, >260 Kd, 10ug/ml
b) 0195-45 (ME 9545), IgG1, chondroitin sulfate proteoglycan, >260 Kd
2. a) 691-I-5-Nu4B (ME Nu4B), IgG2a, p130 Kd, 105 Kd, Vitronectin receptor, 34ug/ml
b) 403-77-4-2 (77), IgG1, p120/94 Kd, Vitronectin receptor (v3, epitope B) c) SAP-52-8, IgG1, 97 Kd, Vitronectin receptor (3), 32ug/ml
3. a) A32, IgG1, Mel-CAM/MUC18, p113 Kd, 13ug/ml, domain 2
b) MN-4, IgG1 k, (PVA-I-2C7-C), recMel-CAM, extracellular domain, domain 4 14ug/ml
c) MN-10, IgG1 k, (PVA-II-1H6-F10), recMel-CAM, extracellular domain, domains also not known for MN-17, MN-14, MN-17, MN-2
d) MN-3, IgG1 k, (PVA-2C5-A), recMel-CAM, extracellular domain, domain 1
e) MN-7, IgG1 k, (PVA-II-1 H3-D11 ), recMel-CAM, extracellular domain, domain 1
f) MN-9, IgG1 k, ( PVA-II-1B6-E11), recMel-CAM, extracellular domain, domain2
g) MN-5, IgG1 k, (PVA-I-4F5-A), recMel-CAM, extracellular domain, domain 5
h) MN-11, IgG1 k(PVA II-1F7-C8), recMel-CAM, extracellular domain, domain 2
i) MN-8, IgG1 k(PVA II-1H4-F10), recMel-CAM, extracellular domain, domain 2
4. a) PS/2, IgG2b, alpha 4 of VLA-4 (rat/mouse), (ATCC 1911-CRL)
b) TS2/16.2.1, IgG1, ß1 of VLA1ß (ATCC 243-HB), 90ug/ml
c) TS2/7.1.1, IgG1, alpha 1 of VLA-1 (ATCC 245-HB), 122ug/ml
5. P8B1, IgG2b, VCAM-1 (Hybridoma Bank, Iowa), blocking

III. Growth Factor Receptors
1. a) 200-3-G6-4-6 (ME 20.4), IgG1, NGF-receptor, 56ug/ml b) I182-11 (ME 82-11), IgG1, NGF-receptor, 40ug/ml
2. a) 425-3-75-5-4 (425), IgG2a, EGF-receptor b) 403-75-7 (75), IgG1, EGF-receptor
3. IR1, IgG1, Insulin receptor (ATCC)

 

IV. Tenascin and Fibronectin
1. 302-2-E5-10-2 (302-1), IgG1, Tenascin
2. 300-3-A7-3-1 (300-3), IgG1, Tenascin, 39ug/ml
3. 300-2-E10-2 (300-2), IgG1, Tenascin
4. 302-1-E9-9-5 (302-9), IgG1, Tenascin, 213ug/ml
5. 300-2-D2-1-8 (300-1), IgG1, Tenascin
6. HFN 7.1, IgG1, Fibronectin (ATCC)
7. M3F7, IgG, type IV collagen, 2 subunits, 185 and 175 kDa [(a1 (IV), a2 (IV)], Hybridoma Bank, Iowa

V. Class I and Class IIMHC Antigens
1. 691-13-17 (13-17), IgG1, HLA-DR, 16ug/ml
2. SK 37-7 (37-7), IgG2a, HLA-DR + DQ
3. B228-8 (28-8), IgG2a, HLA-DR + DQ
4. a) 203-2A6-B11-3 (20.11), IgG1, HLA DQ
b) 56-1-4 (56-1-4), IgG1, HLA DQ
5. W6/32, IgG2a, HLA A, B, C (ATCC), ascitis

VI. Melanocyte-Associated Antigens
1. 505-1-1-9 (505), IgG1, 115ug/ml
2. K, IgG1, ug/ml
3. Q, IgG1, 23ug/ml
4. 2G-10, IgG1, tyrosinase (P. Natali, Rome)

VII. Melanotransferrin
JD6-C9-Cl 3 (ME D63), IgG2a, p97 Kd

 

VIII. Highly Glycosylated Proteins
1. a) 149-2-A2-Cl 17 (ME 49.1), IgG1, p30-60 Kd (CD63), 70ug/ml
b) 404-101-4-5 (101), IgG1, p30-50 Kd (weakly crossreactive to CD63)
c) 506-2-20-7 (506), IgG3, p30-50 Kd (CD63)
d) 439-1-67-6-1 (67-6), IgG2b, p40-70 Kd (crossreactive with CD63)

IX. Cell Surface Proteases
452-2-D1-2 (452), IgG1, 143 Kd, CD13 (aminopeptidase)

X. Growth factors and cytokines
1. a) bFGF-8, IgG1 k, 17.2ug/ml, recbFGF
b) bFGF-11, IgG1 k, 35ug/ml, recbFGF

2. a) MCP-31-B, 2.01ug/ml, recMCP-1
b) MCP-1-D10-1, recMCP-1, IgG1 k, 60.8 ug/ml
c) MCP-1-D10-3, recMCP-1, IgG1 k, 36ug/ml
d) rabbit polyclonal against recMCP-1

3. a) IL-8 2H1-H6, rec. IL-8, IgG1 k, 21.25ug/ml
b) IL-8 2H9-A12, rec. IL-8

4. a) VEGF I 4F6-B11, rec.VEGF, IgM
b) VEGF II 3F4-C4, rec.VEGF, IgM

5. a) HBP17-3G11-A5, rec.HBP17, IgG 1,k
b) HBP175F8-A3, rec. HBP17, IgG1,k

6. a) PDGF B 1H1-A7, Sup. Of Ad5-infected cells, IgG1,k
b) 127.5.7.3.1, PDGF AA and PDGF AB (anti-AA), IgG1, (ATCC)
c) 127.8.2.2.2, rec.PDGF AA, IgG2b, (ATCC)
d) 120.1.2.1.2, PDGF BB, IgG1, (ATCC)
e) 121.6.1.1.1, PDGF BB and PDGF AB (anti-BB), IgG1 (ATCC)

XI. Other
1. Anti-Fibroblasts
a) 451-1-C7-1 (451), IgG1, 59ug/ml

2. Anti-Carbohydrates
a) 456-1-A11-1-2 (456), IgG2a, p120 Kd, 18ug/ml
b) HNK1, IgM (ATCC)
c) 439-3-27-2-3, IgG1 k, (27.2),22ug/ml

3. Oncogenes and Suppressor genes
1. a) p16-25, IgG1 k, 15ug/ml, recp16
b) p16-D8-1, recp16, IgG1 k, 45ug/ml
c) p16-D8-2, recp16, IgG1 k, 32ug/ml
d) p16-D8-3, recp16, IgG1 k, 23.2ug/ml
e) p16-D8-4, recp16, IgG1 k, 32ug/ml

2. a) YY1-D25-C-1, recYY1,
b) YY1-D25-E-1, rec YY1,
c) YY1-D25-F-1, recYY1

3. a) MITF-D35-A9, recMITF
b) MITF D35-E3 , recMITF
c) MITF- D35-D3, recMITF

4. Adenoviruses
a) Ad-B9, 1.86ug/ml, adenolacZ
b) Ad-C12, 17.55ug/ml, adenolacZ
c) 2Hx-2, IgG2a, (ATCC HB-8117), Hela inf. with Adenovirus 2, subgr. A-E

5. Not Characterized
a) 178-2-18-10 (ME 77.1), IgG1, p120 Kd, 38ug/ml
b) I175-29-6 (ME 7529), IgG1, p120 Kd, 33ug/ml
c) H77736 (ME 7736), IgG2b, p125 K, 104 K, 99 Kd
d) 507-2-2-4 (507), IgG1
e) IM-1650-11-4 (#6), IgG1,
f) 3-1-40-2 (#12), IgG1,